The $12M milestone is a positive signal of program progress and partnership health, but the stock's next major catalyst is the 12-month data readout from earlier ABATE cohorts expected in Q2 2026. Traders should watch for that data release and any updates on Takeda's option exercise decision, which would trigger additional payments and de-risk the program.
Price Chart
Executive Summary
AC Immune dosed the first patients in Cohort AD4 of the Phase 1b/2 ABATE trial for its anti-Abeta Alzheimer's immunotherapy ACI-24, triggering a $12 million milestone payment from partner Takeda. The milestone validates program progress and provides non-dilutive capital, while the upcoming 12-month data readout from earlier cohorts in Q2 2026 is the next key catalyst.
Key Financial Metrics
Key Facts
- First patients dosed in Cohort AD4 of the Phase 1b/2 ABATE trial for ACI-24
- Milestone triggers $12 million payment from Takeda
- 12-month data from Cohorts AD1, AD2, AD3 expected Q2 2026
- AC Immune received $100M upfront from Takeda; eligible for up to ~$2.1B in milestones plus tiered double-digit royalties
- ACI-24 is generally safe and well tolerated with anti-Abeta antibody responses at all tested doses
Financial Impact
$12 million milestone payment from Takeda triggered; AC Immune already received $100M upfront and is eligible for up to ~$2.1B in total milestones plus royalties
Risk Factors
- Phase 1b/2 data may not support continued development or option exercise by Takeda
- Alzheimer's immunotherapy is a competitive and high-risk space with frequent clinical failures
- Stock is small-cap biotech with limited liquidity and high volatility around data readouts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3284675 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | 3/A | $2.45 $2.40 | ▼ −2.04% | ▼ −2.03% | $2.25 (−8.16%) |
Oct 9, 2026 18d ago | 3 | $2.50 $2.45 | ▼ −2.00% | ▼ −1.94% | $2.25 (−10.00%) |
Oct 2, 2026 25d ago | 6-K | $2.73 $2.71 | ▼ −0.55% | ▼ −1.22% | $2.25 (−17.43%) |
Sep 23, 2026 4w ago | 6-K | $2.83 $2.66 | ▼ −6.01% | ▼ −5.92% | $2.25 (−20.49%) |
Sep 3, 2026 7w ago | 6-K | $2.93 $2.86 | ▼ −2.39% | ▼ −2.00% | $2.25 (−23.21%) |
Aug 20, 2026 9w ago | 6-K | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 20, 2026 9w ago | Press Release | $2.64 $2.90 | ▲ +9.85% | ▲ +9.44% | $2.25 (−14.77%) |
Aug 11, 2026 11w ago | 6-K | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 11, 2026 11w ago | Press Release | $2.54 $2.62 | ▲ +3.15% | ▲ +2.90% | $2.25 (−11.42%) |
Aug 5, 2026 11w ago | 6-K | $2.29 $2.32 | ▲ +1.31% | ▲ +1.47% | $2.25 (−1.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers